Melissa Palmer, MD
CEO of Liver Consulting LLC
Melissa Palmer, MD is a hepatologist with more than 30 years experience as a key opinion leader (KOL) in the field of liver disease.
Melissa Palmer, MD is a hepatology consultant to the biotech/pharmaceutical industry on full life cycle liver disease development– from discovery to launch and commercialization. Melissa Palmer, MD has extensive expertise in innovative trial design, liver signal evaluation, DMC, ad board, regulatory interactions, commercialization, CI, Due diligence, trial recruitment.
Melissa Palmer, MD is a internationally renowned in the field of hepatology (KOL), and an experienced biotech/pharma executive. She was in a solo practice devoted to treating and evaluating patients with liver disease until 2009, at which time she became a Full Clinical Professor at NYU Langone and Director of Hepatology at NYU Plainview. Since 1991, Melissa Palmer, MD has served as a consultant to more than 25 biopharma companies as a liver disease expert. Dr. Palmer left NYU Langone to become Senior Vice President of Clinical Research and Head of Hepatology at Kadmon Corporation. After 1 year, Dr. Palmer was promoted to Global Head of Hepatology, and became Senior Vice President of Pharmacovigilance in addition to SVP of Clinical Research.
Melissa Palmer, MD left Kadmon in 2015 to become the Global Clinical Lead on Shire’s NASH program, as well as to consult on other liver-related issues within Shire– such as cholestatic liver disease, pediatric liver disease and liver-related safety issues (DILI), and was rapidly promoted to Global Development Lead – Hepatology. Shire was acquired by Takeda in 2019 and Dr. Palmer was made Head of Liver Disease Development at Takeda.
Melissa Palmer, MD is currently a hepatology consultant, and is the CEO of Liver Consulting LLC. She is consulting on innovative trial designs for NASH and other liver diseases such as PSC, as well as regulatory interactions. Dr. Palmer has co-authored numerous joint FDA guidelines, and has extensive experience with
liver signal evaluation during clinical trials, (DILI), formation of ad boards, DSMC, commercialization and pipeline assessment.
Melissa Palmer, MD graduated from Columbia University with a B.A. and was trained in Hepatology (as well as medical school) at Mount Sinai School of Medicine in New York City. She has authored numerous medical and lay-public books, and book chapters, and has contributed to three encyclopedias on various liver-related topics. Melissa Palmer, MD is the author of the best-selling book “Dr. Melissa Palmer’s Guide to Hepatitis & Liver Disease.” Her scientific publications in the field of Hepatology have appeared in such peer-reviewed journals as Hepatology, Gastroenterology, Seminars of Liver Disease, Transplantation, AP&T and she is a contributing editor of several peer-reviewed journals.
Melissa Palmer, MD is a liver disease consultant whose specialties include: Hepatology, Nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) Liver Disease, Clinical Research, Pharmacovigilance, Clinical trial Innovation. Drug Development, Cholestatic Liver disease, Drug-Induced Liver Injury, DILI , cholestatic liver disease, primary Biliary cholangitis, Primary sclerosing cholangitis (PSC), Phase 1,2,3, Hepatitis, PFIC
Melissa Palmer, MD can be contacted at firstname.lastname@example.org